ELTP - Elite Pharmaceuticals, Inc.
| Previous Close | 0.09 |
| Open | 0.09 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 0.09 - 0.09 |
| 52 Week Range | 0.06 - 0.22 |
| Volume | 371,457 |
| Avg. Volume | 450,493 |
| Market Cap | 71.237M |
| Beta | 1.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 |
| Earnings Date | Feb 9, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE•2 months ago
New Research: Key Drivers of Growth for U.S. Stem Cell Inc. and Elite Pharmaceuticals - Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, NY / ACCESSWIRE / March 7, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of U.S. Stem Cell Inc. ( OTCQB: USRM ) and Elite Pharmaceuticals Inc. ...
- ACCESSWIRE•3 months ago
Elite Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 12, 2018 / Elite Pharmaceuticals, Inc. (OTCQB: ELTP ) will be discussing their earnings results in their Q3 Earnings Call to be held on February 12, 2018 at 11:30 AM ...
Capital Cube•11 months agoElite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q4, 2017 By the Numbers : June 16, 2017
Categories: Yahoo FinanceGet free summary analysis Elite Pharmaceuticals, Inc. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Elite Pharmaceuticals, Inc. – Mylan N.V., Acura Pharmaceuticals, Inc., Cambrex Corporation, Aceto Corporation, Nektar Therapeutics, Pfizer Inc. and Albany Molecular Research, Inc. (MYL-US, ACUR-US, CBM-US, ACET-US, NKTR-US, PFE-US ... Read more (Read more...)